Close on 09 Oct 2026
All US Equities (S&P 500 / NASDAQ-100)

Bristol Myers Squibb

BMYUS Listed
Exchange: NYSE · Market: US Equities · Currency: USD

Bristol Myers Squibb (BMY) is a leading publicly traded corporation listed in the United States, constituent of the S&P 500 index.

Sector: Health Care·Indices: S&P 500·Market Cap: $117.62B
Close on 16 Oct 2026
$59.75
-0.82 (-1.35%)
Last updated: 16 Oct 2026 (US Market EOD settlement)

Stock Snapshot & Key Numbers — Bristol Myers Squibb

Verified Daily Close

Official closing price, 1-year price range, valuation multiples, and market value from exchange records.

Last Session Move
Down -1.35% on 16 Oct 2026
Position vs 1-Year High
12.2% below 52W High
P/E Valuation Multiple
12.7x (Under 20x)
Annual Cash Dividend
4.26% Dividend Yield
Close on 16 Oct 2026
$59.75
-0.82 (-1.35%)vs prev close
1-Year Low to High Range67% of range
Low: $43High: $68
Valuation (P/E, P/B & Dividend)
P/E Ratio (Price / Profit):12.7x
P/B Ratio (Price / Book):5.3x
Dividend Yield:4.26%
Total Company Value (Market Cap)
$117.62B
Sector: Health Care
Latest Official Announcement:Dr Reddy's Q1 net profit falls 69% to Rs 443 crore on semaglutide inventory costs - Moneycontrol.com
2mo ago
Plain-English Company Summary

Bristol Myers Squibb (BMY) is a US equity security listed on the NYSE. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at $59.75, recording a -0.82 (-1.35%) decline from its previous close of $60.57. Over the trailing 52-week trading cycle, BMY has traded between a 52-week low of $42.60 and a 52-week high of $68.09, establishing its annual trading channel. In historical performance, Bristol Myers Squibb has gained 37.7% over the past 1 year. Period returns across standard measurement intervals include: 1-week: +1.07%, 1-month: -6.05%, 6-month: +1.34%, 1-year: +37.7%, 3-year: +4.51%, 5-year: +4.94%. Daily reported trading volume reached 13,770,800 equity shares. On key valuation multiples as of Oct 13, 2026, the company trades at a trailing price-to-earnings (P/E) multiple of 12.7x and a price-to-book (P/B) ratio of 5.3x, with a trailing dividend yield of 4.26%. Its market capitalization stands at $117.62B. The company is categorized under the Health Care sector and S&P 500 industry within the US equities universe.

Price Chart

1Y: +37.70% (₹16.36)
₹68₹59₹51₹43Thu, 16 Oct, 2025Fri, 16 Oct, 2026

Trading Multiples & Ranges

Price boundaries and liquidity distribution.

52-Week Range$42.60 – $68.09
Low: $42.60High: $68.09
$42.60$68.09
Trailing P/E Ratio12.68x
Price to Book (P/B)5.27x
Dividend Yield4.26%
Day High / Low$59.54 – $61.43
Daily Volume13.77M

Past Price Win/Loss Odds (1-Week, 1-Month, 3-Month)

How often this stock rose, stayed flat, or fell over past 21-day holding periods (based on historical data, not a future prediction).

1 Month Holding Period (21 trading days)
1,234 past 21-day periods analyzed
Fell 20.9%
Within ±5% (55.7%)
Rose 23.4%
Fell > 5%
20.9%
258 windows
Within ±5%
55.7%
687 windows
Rose > 5%
23.4%
289 windows
In 80% of past 1 month windows the move was within ±8.4%.
Historical outcomes of this stock's own price. Not a forecast. (1255 trading days of history).
How to read historical odds

At-a-Glance Health & Momentum Check

Market Mood: Consolidation / Rangebound
News Activity
STABLE
Recent announcement pace
Profit & Margin Trend
NEUTRAL
Earnings & margin direction
Economy Sensitivity
MODERATE
Impact of rates, oil & FX
Broad Market Mood
Consolidation / Rangebound
Current market trend
News Tone
NEGATIVE SCRUTINY
Recent filing tone
What This Means(based on reported financials)

Company filings and balance-sheet numbers show steady day-to-day operations with stable margins and working capital.

Active Risk Flags & Monitoring Constraints
Standard systemic equity market and interest rate cycle exposure

How Outside Factors Affect This Stock (Market, Crude Oil & Currency)

How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.

Swing Rank: 50th percentile
Typical 1-Year Price Swing (Volatility): 27.6% annualized
Price Swing Level vs Market: Moderate Swings
Factor / Benchmark1Y Beta (Sensitivity)1Y Correlation (-1 to +1)What This Means
S&P 500+0.21+0.10Trailing 1Y historical sensitivity: a 1% move in S&P 500 coincided with a +0.21% co-movement (correlation: 0.10). Descriptive historical relationship, not predictive.
US 10Y Treasury Yield-0.37-0.20Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a -0.37% co-movement (correlation: -0.20). Descriptive historical relationship, not predictive.
Brent Crude Oil-0.08-0.15Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.08% co-movement (correlation: -0.15). Descriptive historical relationship, not predictive.
USD / INR+0.35+0.09Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a +0.35% co-movement (correlation: 0.09). Descriptive historical relationship, not predictive.
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾

Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.

Trailing Returns Breakdown

Calendar-aligned historical percentage performance across standard market windows.

PeriodStart PriceCurrent PriceReturn (%)
1 Week₹59.12₹59.75+1.07%
15 Days₹61.46₹59.75-2.78%
1 Month₹63.60₹59.75-6.05%
3 Months₹60.51₹59.75-1.26%
6 Months₹58.96₹59.75+1.34%
1 Year₹43.39₹59.75+37.70%
3 Years₹57.17₹59.75+4.51%
5 Years₹56.94₹59.75+4.94%

Price Swings & Biggest Historical Drops

How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.

1Y Yearly Swing
27.6%
Annualized volatility
1Y Beta vs Index
0.22
vs benchmark index
Biggest 1Y Drop
-16.8%
1Y peak-to-low drop
Biggest 5Y Drop
-51.1%
5Y peak-to-low drop
vs 52W High
-12.3%
Distance from 1Y high
vs 52W Low
+40.3%
Gain above 1Y low

Calendar-Year Historical Performance

Annual performance breakdown comparing first and last closing sessions of each calendar year.

Calendar YearStart CloseEnd CloseAnnual ReturnTrajectory Bar
CY 2026₹53.46₹59.75+11.8%
CY 2025₹56.79₹53.94-5.0%
CY 2024₹52.76₹56.56+7.2%
CY 2023₹72.26₹51.31-29.0%
CY 2022₹61.88₹71.95+16.3%
CY 2021₹56.94₹62.35+9.5%

Corporate Actions History

No dividend or stock split distributions recorded in historical feeds for BMY.

Historical Investment Simulator

Factual simulation of past returns in Bristol Myers Squibb (BMY) using real recorded closing prices.

₹1,00,000.00
5 Years
Principal Invested
₹1,00,000.00
₹1,00,000.00 starting capital
Portfolio Value Today
₹1,04,935.00
Based on latest close
Absolute Return
+4.9%
+₹4,935.00
Annualized (CAGR)
+1.0%
Compound annual growth
Entry Price: ₹56.94 · Exit Price: ₹59.75
Simulated 5Y period (INR)

Recent News & Official Exchange Announcements

Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.

Showing 5 of 5 Updates
#1 EARNINGSLODR Materiality: 98/100Business HeadwindBackground Context
2mo ago

Dr Reddy's Q1 net profit falls 69% to Rs 443 crore on semaglutide inventory costs - Moneycontrol.com

Dr Reddy's Q1 net profit falls 69% to Rs 443 crore on semaglutide inventory costs Moneycontrol.com

Valuation Impact:-2.5% to -6.0% (EBITDA Margin Compression Risk)
Outlay:₹443 Cr
Inspecting in Causal Panel
Source: Moneycontrol.com·Horizon: IMMEDIATE
SEBI LODR Reg 30 Mapped
#2 EARNINGSLODR Materiality: 82/100Neutral / RoutineBackground Context
5mo ago

Dr Reddy's Q4 PAT crashes 86% on generic Revlimid shock in US market - Business Standard

Dr Reddy's Q4 PAT crashes 86% on generic Revlimid shock in US market Business Standard

Valuation Impact:±1.0% (In-line Quarterly Disclosure)
Click to analyze
Source: Business Standard·Horizon: IMMEDIATE
SEBI LODR Reg 30 Mapped
#3 GENERALLODR Materiality: 64/100Neutral / RoutineOngoing Impact
1mo ago

Dr Reddy’s launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment - Moneycontrol.com

Dr Reddy’s launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment Moneycontrol.com

Valuation Impact:±0.5% (Neutral Fundamental Range)
Click to analyze
Source: Moneycontrol.com·Horizon: SHORT_TERM
SEBI LODR Reg 30 Mapped
#4 GENERALLODR Materiality: 64/100Neutral / RoutineBackground Context
2mo ago

Piramal Pharma seeing broad-based revival in CDMO, complex generics, says Nandini Piramal - Moneycontrol.com

Piramal Pharma seeing broad-based revival in CDMO, complex generics, says Nandini Piramal Moneycontrol.com

Valuation Impact:±0.5% (Neutral Fundamental Range)
Click to analyze
Source: Moneycontrol.com·Horizon: SHORT_TERM
SEBI LODR Reg 30 Mapped
#5 GENERALLODR Materiality: 60/100Neutral / RoutineBackground Context
2mo ago

Stock Market Today: Live Updates 02.08.2026 - TechStock²

Stock Market Today: Live Updates 02.08.2026 TechStock²

Valuation Impact:±0.5% (Neutral Fundamental Range)
Click to analyze
Source: TechStock²·Horizon: SHORT_TERM
SEBI LODR Reg 30 Mapped

Why This Matters for the Business

Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.

Event 1 of 5
Causal Attribution in Focus
EARNINGS·2mo ago
Verified Exchange / Wire Disclosure:
Dr Reddy's Q1 net profit falls 69% to Rs 443 crore on semaglutide inventory costs - Moneycontrol.com
Source: Moneycontrol.com·LODR Materiality: 98/100Headwind₹443 Cr Outlay
3-Stage Transmission Mechanism:
1. Disclosure Trigger
Quarterly Financial Milestone & Operating Margins
2. Sector Transmission
Sector-wide volume demand absorption & operating leverage
3. BMY Accretion
-2.5% to -6.0% (EBITDA Margin Compression Risk)
Causal Attribution Analysis:Primary Value-Chain Beneficiary

Operating performance or EBITDA margins lagged market expectations, triggering multiples compression.

Extracted Factual Evidence:
  • •Transaction / financial magnitude identified at ₹443 Cr
  • •Direct quantitative change registered at 69%
  • •Top-line revenue or operating profitability registered contraction vs previous comparative period
P&L Operating Leverage

Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across health care units.

Order Book & Revenue Visibility

Identified project outlay of ₹443 Cr secures forward multi-quarter top-line visibility.

Affected Financial Metrics:
Operating EBITDA MarginRevenue VisibilityNet Income (PAT)
Cross-asset macro betas (Brent Crude, USD/INR, NIFTY) are mapped in the dedicated dependency engine.
View Graph
Evidence Integrity: Hypotheses and attribution models are anchored strictly in verified regulatory disclosures, public tenders, and audited financial statements across a trailing 6-month capital cycle.

Common Questions About Bristol Myers Squibb (BMY)

Key facts on BMY share price, historical returns, valuation ratios, and past SIP performance.

What is the current share price and 52-week range of Bristol Myers Squibb (BMY)?

As of 16 Oct 2026, the official closing share price of Bristol Myers Squibb (BMY) on NYSE is $59.75 (-1.35% vs the previous close). Over the past 52 weeks, BMY has traded between a low of $42.60 and a high of $68.09, with a reported market capitalization of $117.62B.

What are the historical returns of Bristol Myers Squibb (BMY)?

Based on split-adjusted closing prices through 16 Oct 2026, Bristol Myers Squibb (BMY) recorded the following trailing price returns: 1 Week: +1.07% (from $59.12 to $59.75); 15 Days: -2.78% (from $61.46 to $59.75); 1 Month: -6.05% (from $63.60 to $59.75); 3 Months: -1.26% (from $60.51 to $59.75); 6 Months: +1.34% (from $58.96 to $59.75); 1 Year: +37.70% (from $43.39 to $59.75); 3 Years: +4.51% (from $57.17 to $59.75); 5 Years: +4.94% (from $56.94 to $59.75). Past performance reflects historical exchange records and does not predict future returns.

What is the P/E ratio, P/B ratio, and dividend yield of Bristol Myers Squibb (BMY)?

Bristol Myers Squibb (BMY) currently trades at a trailing Price-to-Earnings (P/E) ratio of 12.7x, a Price-to-Book (P/B) ratio of 5.3x, and a trailing 12-month dividend yield of 4.26%. It operates in the Health Care sector (S&P 500).

How much would a past lump-sum or monthly SIP investment in BMY have grown?

Based on historical closing prices for Bristol Myers Squibb (BMY): A one-time lump-sum investment of $10000.00 held for 5 years would be worth $10493.50 (+4.9% total return, 1.0% CAGR), while a monthly SIP of $500.00 over 5 years (total invested: $30500.00) would be worth $31638.56 (+3.7% absolute return). You can test custom amounts and holding periods in the interactive calculator above.